All News

Research presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting emphasizes the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.

The findings suggest the presence of CHIP before HCT may have potential to serve as a biomarker for CVD risk after HCT in patients with multiple myeloma.

In a systematic and meta-analysis review of cohort studies that featured nearly 1.7 million individuals, study authors concluded that there is an association between high body mass index (BMI) and an increased risk of incident type 1 diabetes.

The implementation of a mailed stool test program increased colorectal cancer (CRC) screen-up-to-date rates compared with lower-intensity interventions, such as patient letters.

Durable mechanistic effects and a good safety profile were found in patients who took mitapivat for sickle cell disease (SCD).

Women of varying backgrounds, educational levels, and marriage status opted for different types of breast reconstruction based on different values.

Adzynma is the first product to be approved for the treatment of the rare blood disorder that has 90% mortality when left untreated.

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, discussed how infusion therapy can be administered as ambulatory drug infusion and its relation to biosimilars.

A senator opposes the Biden drug price negotiation plan and proposes a new model to help manage weight loss drug costs; Black children are underdiagnosed with attention-deficit/hyperactivity disorder (ADHD) compared with their White peers; lawmakers and witnesses said that policy makers must balance innovation with potential harms when it comes to artificial intelligence (AI) in health care.

In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to expand personalized medicine.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Residents grew more knowledgeable and more comfortable with using pre-exposure prophylaxis (PrEP) drugs for prevention against HIV after training was included in their residency program.

Recor Medical announced the FDA approval of its Paradise Ultrasound Renal Denervation system for the treatment of hypertension on November 7, 2023.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

Sophia Humphreys, PharmD, MHA, BCBBS, spoke about how she views formulary management as a team approach.

An online survey of patients from multiple countries has shed light on their challenges in getting proper care for ovarian cancer.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Industry stakeholders and patient advocacy groups are raising concerns with CMS due to high denial rates for non-invasive ventilators (NIVs) by Medicare Advantage plans.

Investigators propose potential payment models for gene therapies that consider equitable patient access and payer reimbursement.

Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.